Sidoti Equities Analysts Lift Earnings Estimates for Cibus

Cibus, Inc. (NASDAQ:CBUS) – Equities research analysts at Sidoti increased their Q1 2026 earnings estimates for Cibus in a research note issued on Thursday, March 19th. Sidoti analyst A. Hantman now forecasts that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.36). The consensus estimate for Cibus’ current full-year earnings is ($2.96) per share. Sidoti also issued estimates for Cibus’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.18) EPS, Q1 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.88) EPS.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.01. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%. The company had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $1.64 million.

CBUS has been the subject of several other reports. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of Cibus in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.00.

Cibus Price Performance

Shares of NASDAQ:CBUS opened at $2.48 on Monday. The stock has a market cap of $134.61 million, a PE ratio of -0.83 and a beta of 1.62. The company’s fifty day moving average is $2.65 and its 200 day moving average is $1.91. Cibus has a 52 week low of $1.09 and a 52 week high of $4.19. The company has a quick ratio of 0.72, a current ratio of 0.72 and a debt-to-equity ratio of 1.37.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CBUS. Certior Financial Group LLC raised its holdings in Cibus by 6.5% during the 3rd quarter. Certior Financial Group LLC now owns 184,786 shares of the company’s stock valued at $238,000 after buying an additional 11,230 shares during the last quarter. Transce3nd LLC grew its holdings in Cibus by 29.1% in the 2nd quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock worth $75,000 after acquiring an additional 11,861 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cibus by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock valued at $479,000 after acquiring an additional 12,467 shares during the period. Raymond James Financial Inc. increased its position in shares of Cibus by 31.0% in the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after acquiring an additional 12,722 shares during the period. Finally, PACK Private Wealth LLC bought a new position in shares of Cibus during the fourth quarter valued at about $27,000. 33.81% of the stock is owned by hedge funds and other institutional investors.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.